ALUNBRIG® (brigatinib) Expert Opinion Video Series: Managing toxicities and side effects associated with ALUNBRIG
Prescribing information is available at the top of the page.
Listen to Dr Sharmistha Ghosh who shares her experience on the management of patients with ALK+ aNSCLC during treatment with ALUNBRIG, including the specific monitoring required.
Dr Ghosh highlights the recommended information and advice to support your patients during treatment with ALUNBRIG, and also shares her practical recommendations for the appropriate management of adverse reactions associated with ALUNBRIG for optimal management of your patients with ALK+ aNSCLC.
ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; aNSCLC, advanced non-small cell lung cancer.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
